BACKGROUND: This analysis explored the prevalence and correlates of pain in patients enrolled in methadone maintenance treatment (MMT). METHODS: Patients in two MMT programs starting a hepatitis care coordination randomized controlled trial completed the Brief Pain Inventory Short-Form and other questionnaires. Associations between clinically significant pain (average daily pain≥5 or mean pain interference≥5 during the past week) and sociodemographic data, medical status, depressive symptoms, and health-related quality of life, and current substance use were evaluated in multivariate analyses. RESULTS: The 489 patients included 31.8% women; 30.3% Hispanics, 29.4% non-Hispanic Blacks, and 36.0% non-Hispanic Whites; 60.1% had hepatitis C, 10.6% had HIV, and 46.8% had moderate or severe depressive symptomatology. Mean methadone dose was 95.7mg (SD 48.9) and urine drug screening (UDS) was positive for opiates, cocaine, and amphetamines in 32.9%, 40.1%, and 2.9%, respectively. Overall, 237 (48.5%) reported clinically significant pain. Pain treatments included prescribed opioids (38.8%) and non-opioids (48.9%), and self-management approaches (60.8%), including prayer (33.8%), vitamins (29.5%), and distraction (12.7%). Pain was associated with higher methadone dose, more medical comorbidities, prescribed opioid therapy, and more severe depressive symptomatology; it was not associated with UDS or self-reported substance use. CONCLUSIONS:Clinically significant pain was reported by almost half of the patients in MMT programs and was associated with medical and psychological comorbidity. Pain was often treated with opioids and was not associated with measures of drug use. Studies are needed to further clarify these associations and determine their importance for pain treatment strategies.
RCT Entities:
BACKGROUND: This analysis explored the prevalence and correlates of pain in patients enrolled in methadone maintenance treatment (MMT). METHODS:Patients in two MMT programs starting a hepatitis care coordination randomized controlled trial completed the Brief Pain Inventory Short-Form and other questionnaires. Associations between clinically significant pain (average daily pain≥5 or mean pain interference≥5 during the past week) and sociodemographic data, medical status, depressive symptoms, and health-related quality of life, and current substance use were evaluated in multivariate analyses. RESULTS: The 489 patients included 31.8% women; 30.3% Hispanics, 29.4% non-Hispanic Blacks, and 36.0% non-Hispanic Whites; 60.1% had hepatitis C, 10.6% had HIV, and 46.8% had moderate or severe depressive symptomatology. Mean methadone dose was 95.7mg (SD 48.9) and urine drug screening (UDS) was positive for opiates, cocaine, and amphetamines in 32.9%, 40.1%, and 2.9%, respectively. Overall, 237 (48.5%) reported clinically significant pain. Pain treatments included prescribed opioids (38.8%) and non-opioids (48.9%), and self-management approaches (60.8%), including prayer (33.8%), vitamins (29.5%), and distraction (12.7%). Pain was associated with higher methadone dose, more medical comorbidities, prescribed opioid therapy, and more severe depressive symptomatology; it was not associated with UDS or self-reported substance use. CONCLUSIONS: Clinically significant pain was reported by almost half of the patients in MMT programs and was associated with medical and psychological comorbidity. Pain was often treated with opioids and was not associated with measures of drug use. Studies are needed to further clarify these associations and determine their importance for pain treatment strategies.
Authors: Jodie A Trafton; Elizabeth M Oliva; Doyanne A Horst; Jared D Minkel; Keith Humphreys Journal: Drug Alcohol Depend Date: 2004-01-07 Impact factor: 4.492
Authors: San Keller; Carla M Bann; Sheri L Dodd; Jeff Schein; Tito R Mendoza; Charles S Cleeland Journal: Clin J Pain Date: 2004 Sep-Oct Impact factor: 3.442
Authors: Andrew Rosenblum; Herman Joseph; Chunki Fong; Steven Kipnis; Charles Cleland; Russell K Portenoy Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Declan T Barry; Mark Beitel; Christopher J Cutter; David A Fiellin; Robert D Kerns; Brent A Moore; Lindsay Oberleitner; Lynn M Madden; Christopher Liong; Joel Ginn; Richard S Schottenfeld Journal: Drug Alcohol Depend Date: 2018-11-13 Impact factor: 4.492
Authors: Margaret L Griffin; Katherine A McDermott; R Kathryn McHugh; Garrett M Fitzmaurice; Robert N Jamison; Roger D Weiss Journal: Drug Alcohol Depend Date: 2016-04-25 Impact factor: 4.492
Authors: Kelly E Dunn; Patrick H Finan; D Andrew Tompkins; Michael Fingerhood; Eric C Strain Journal: Drug Alcohol Depend Date: 2015-10-19 Impact factor: 4.492
Authors: Declan T Barry; Jonathan D Savant; Mark Beitel; Christopher J Cutter; Richard S Schottenfeld; Robert D Kerns; Brent A Moore; Lindsay Oberleitner; Michelle T Joy; Nina Keneally; Christopher Liong; Kathleen M Carroll Journal: J Addict Med Date: 2014 Sep-Oct Impact factor: 3.702
Authors: Katharina L Wiest; Jason B Colditz; Kathryn Carr; Victoria J Asphaug; Dennis McCarty; Paul A Pilkonis Journal: J Addict Med Date: 2014 Nov-Dec Impact factor: 3.702
Authors: Lindsay M Oberleitner; Mark Beitel; Richard S Schottenfeld; Robert D Kerns; Christopher Doucette; Renee Napoleone; Christopher Liong; Declan T Barry Journal: J Addict Med Date: 2016 Jan-Feb Impact factor: 3.702
Authors: Roger D Weiss; Jennifer Sharpe Potter; Margaret L Griffin; R Kathryn McHugh; Deborah Haller; Petra Jacobs; John Gardin; Dan Fischer; Kristen D Rosen Journal: J Subst Abuse Treat Date: 2014-04-04
Authors: Bohdan Nosyk; Jeong E Min; Guillaume Colley; Viviane D Lima; Benita Yip; M-J S Milloy; Evan Wood; Julio S G Montaner Journal: AIDS Date: 2015-05-15 Impact factor: 4.177